69 related articles for article (PubMed ID: 11804273)
1. Technology evaluation: T-cell activator, Xenova.
Knutson KL
Curr Opin Mol Ther; 2001 Dec; 3(6):585-8. PubMed ID: 11804273
[TBL] [Abstract][Full Text] [Related]
2. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
Hibbitts S
Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
4. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
6. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
7. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
Tomson TT; Roden RB; Wu TC
Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
[TBL] [Abstract][Full Text] [Related]
9. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccines.
Stanley M
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):279-93. PubMed ID: 16356772
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL.
Reinis M
Curr Opin Mol Ther; 2004 Apr; 6(2):206-11. PubMed ID: 15195933
[TBL] [Abstract][Full Text] [Related]
12. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
13. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine.
Ghim SJ; Sundberg J; Delgado G; Jenson AB
Exp Mol Pathol; 2001 Dec; 71(3):181-5. PubMed ID: 11733943
[TBL] [Abstract][Full Text] [Related]
14. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
16. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
[TBL] [Abstract][Full Text] [Related]
19. Update on human papillomavirus vaccines for cervical cancer.
Steller MA
Curr Opin Investig Drugs; 2002 Jan; 3(1):37-47. PubMed ID: 12054070
[TBL] [Abstract][Full Text] [Related]
20. Strategies against human papillomavirus infection and cervical cancer.
Jung WW; Chun T; Sul D; Hwang KW; Kang HS; Lee DJ; Han IK
J Microbiol; 2004 Dec; 42(4):255-66. PubMed ID: 15650698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
